Clinical trial · Observational
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy
NCT03889951CI-TRIAL-00037789unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. To detect IKZF-1 deletion mutations in patients with ALL. 2. To study the impact of IKZF-1 deletion mutation on therapy of ALL. 3. To study the correlation between IKZF-1 deletion mutations and BCR-ABL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALL, Childhood | Childhood Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- group 1
- description
- group of ALL patients with IKZF1 deletion mutation.
- label
- group 2
- description
- group of ALL patients with no detected mutation
Primary outcomes (2)
- measure
- detection of IKZF-1 deletion mutations in patients with ALL.
- timeFrame
- baseline
- description
- detection of IKZF1 deletion mutation by fluorescent inset hybridization and by PCR.
- measure
- Detection of BCR-ABL translocation.
- timeFrame
- baseline
- description
- by PCR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with acute lymphoblastic leukemia. Exclusion Criteria: * patients with any other hematological malignancies. * patients receiving chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.